Björklund Pharma

Björklund Pharma is an early-stage biopharmaceutical company headquartered in Mo i Rana, Norway, dedicated to the development of therapies that restore physiological function and promote tissue repair. The company's research strategy centers on the therapeutic potential of biofactors and natural compounds, with a significant emphasis on the regenerative peptide Thymosin beta-4 (Tβ4). Björklund Pharma is currently advancing programs targeting a diverse range of chronic and life-threatening conditions, including Multiple Sclerosis, Dry Eye Syndrome, and COVID-19. As a privately held subsidiary of Bolna AS, the company bridges the gap between mechanistic clinical research and the development of targeted nutraceutical and biotech interventions. Its mission is to address complex medical challenges through evidence-based innovation and strategic global collaborations.